EGFR and non-small cell lung carcinoma: There was no difference when analysis was restricted to EGFR positive NSCLC patients (median PFS for WBRT alone (n=25): 9 months (95% CI, 3.6–14.4) vs. 12 months (95% CI, 8.0–15.9) for WBRT plus anti-PD-1 (n=5), p=0.510) (Supplementary Figure 2).